奥泰生物
(688606)
| 流通市值：54.00亿 | | | 总市值：54.00亿 |
| 流通股本：7928.09万 | | | 总股本：7928.09万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,201,122,350.7 | 977,932,225.59 | 1,240,842,598.73 | 1,317,552,525.97 |
| 应收票据及应收账款 | 109,797,352.04 | 111,179,946.99 | 87,785,816.55 | 100,869,677.68 |
| 应收账款 | 109,797,352.04 | 111,179,946.99 | 87,785,816.55 | 100,869,677.68 |
| 预付款项 | 12,906,430.46 | 12,523,896.74 | 16,093,500.93 | 13,057,669.21 |
| 其他应收款合计 | 6,017,984.69 | 7,711,443.31 | 9,305,159.71 | 8,180,260.37 |
| 存货 | 152,694,357.23 | 160,288,048.74 | 161,875,508.42 | 188,594,762.48 |
| 其他流动资产 | 78,134,625.63 | 78,283,401.12 | 82,112,500.63 | 61,839,303.49 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,022,645,424.21 | 3,052,053,838.21 | 3,065,860,380.34 | 3,161,447,852.41 |
| 非流动资产: | | | | |
| 长期股权投资 | 22,012,709.53 | 21,833,957.89 | 21,897,172.16 | - |
| 其他权益工具投资 | 17,847,856.6 | 17,847,856.6 | 17,547,856.6 | 17,547,856.6 |
| 其他非流动金融资产 | 5,400,000 | 5,400,000 | 5,400,000 | 5,400,000 |
| 投资性房地产 | 13,435,637.7 | 13,526,900.1 | 13,618,162.5 | 13,709,424.9 |
| 固定资产 | 488,559,199.53 | 494,812,696.63 | 244,473,263.7 | 248,697,952.1 |
| 在建工程 | 428,628,542.03 | 402,663,243.57 | 595,711,252.33 | 488,254,303.47 |
| 使用权资产 | 8,959,644.12 | 10,599,397.56 | 21,214,420.65 | 22,850,881.8 |
| 无形资产 | 108,689,479.76 | 109,271,074.46 | 109,852,669.16 | 110,434,263.86 |
| 长期待摊费用 | 10,576,771.41 | 12,324,693.05 | 13,890,236.27 | 15,719,408.01 |
| 递延所得税资产 | 26,624,822.46 | 28,049,344.73 | 27,756,953.22 | 30,175,555.03 |
| 其他非流动资产 | 11,284,398 | 10,954,400 | 3,617,940 | 1,820,274.69 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,142,019,061.14 | 1,127,283,564.59 | 1,074,979,926.59 | 954,609,920.46 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,164,664,485.35 | 4,179,337,402.8 | 4,140,840,306.93 | 4,116,057,772.87 |
| 流动负债: | | | | |
| 交易性金融负债 | 28,631,715 | 33,018,098 | 30,285,828 | 25,069,838 |
| 应付票据及应付账款 | 100,613,428.66 | 112,165,910.31 | 105,926,409.4 | 77,609,456.63 |
| 应付账款 | 100,613,428.66 | 112,165,910.31 | 105,926,409.4 | 77,609,456.63 |
| 合同负债 | 32,554,479.97 | 41,129,989.34 | 38,443,498.26 | 41,616,377.76 |
| 应付职工薪酬 | 26,003,240.48 | 25,692,603.19 | 14,646,698.63 | 28,479,225.18 |
| 应交税费 | 80,554,393.54 | 76,662,270.71 | 81,847,577.9 | 82,622,130.5 |
| 其他应付款合计 | 1,762,789.66 | 68,837,085.47 | 1,806,637.13 | 2,348,981.08 |
| 应付股利 | - | 66,124,264.5 | - | - |
| 一年内到期的非流动负债 | 3,940,968.05 | 4,492,081.7 | 11,920,859.28 | 16,256,946.97 |
| 其他流动负债 | 233,570.78 | 228,440.43 | 1,049,179.59 | 160,056.35 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 274,294,586.14 | 362,226,479.15 | 285,926,688.19 | 274,163,012.47 |
| 非流动负债: | | | | |
| 租赁负债 | 4,535,829.03 | 5,819,798.45 | 9,706,893.57 | 7,656,749.97 |
| 递延收益 | 1,900,184.64 | 2,160,104.17 | 2,420,023.7 | 2,679,943.23 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 6,436,013.67 | 7,979,902.62 | 12,126,917.27 | 10,336,693.2 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 280,730,599.81 | 370,206,381.77 | 298,053,605.46 | 284,499,705.67 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 79,280,855 | 79,280,855 | 79,280,855 | 79,280,855 |
| 资本公积 | 1,720,311,310.31 | 1,719,863,795.56 | 1,716,618,114.31 | 1,713,251,291.94 |
| 减:库存股 | 137,864,852.82 | 140,336,281.71 | 140,336,281.71 | 103,402,412.86 |
| 其他综合收益 | 29,275,080.64 | 31,391,480.95 | 30,898,102.62 | 30,753,494.86 |
| 盈余公积 | 266,191,150.02 | 266,191,150.02 | 266,191,150.02 | 266,191,150.02 |
| 未分配利润 | 1,922,410,940.57 | 1,848,763,944.91 | 1,885,963,667.39 | 1,841,174,753.77 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,879,604,483.72 | 3,805,154,944.73 | 3,838,615,607.63 | 3,827,249,132.73 |
| 少数股东权益 | 4,329,401.82 | 3,976,076.3 | 4,171,093.84 | 4,308,934.47 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,883,933,885.54 | 3,809,131,021.03 | 3,842,786,701.47 | 3,831,558,067.2 |
| 负债和股东权益合计 | 4,164,664,485.35 | 4,179,337,402.8 | 4,140,840,306.93 | 4,116,057,772.87 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |